Myriad Genetics: Significantly Undervalued With Profitability In Sight

Group 1 - Myriad Genetics (NASDAQ: MYGN) is initiated at a Buy rating, indicating a favorable investment opportunity at current stock levels [1] - The stock is trading near multi-year lows around $7, suggesting an attractive risk/reward profile [1] - The valuation implies under 1× forward sales despite the company experiencing double-digit revenue growth [1]